Trial Profile
Randomized, Double-blind, Placebo-controlled Study With Open-label Extension Phase to Evaluate the Efficacy and Safety of Avatrombopag for the Treatment of Thrombocytopenia in Pediatric Subjects With Immune Thrombocytopenia for ≥6 Months
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 31 Jan 2024
Price :
$35
*
At a glance
- Drugs Avatrombopag (Primary)
- Indications Idiopathic thrombocytopenic purpura; Thrombocytopenia
- Focus Registrational; Therapeutic Use
- Sponsors Dova Pharmaceuticals
- 24 Jan 2024 Status changed from recruiting to active, no longer recruiting.
- 01 Sep 2023 This trial has been completed in France.
- 19 Jul 2023 Planned primary completion date changed from 2 Jun 2023 to 14 Aug 2023.